Sort   by:  
 Page size 
UnknownHPV16 E7-dependent transformation activates NHE1 through a PKA-RhoA-induced inhibition of p38alpha.
Not available
S-EPMC2568952 | biostudies-literature
UnknownGenomic Profiling of KRAS/NRAS/BRAF/PIK3CA Wild-Type Metastatic Colorectal Cancer Patients Reveals Novel Mutations in Genes Potentially Associated with Resistance to Anti-EGFR Agents.
Not available
S-EPMC6627713 | biostudies-literature
UnknownCetuximab Rechallenge Plus Avelumab in Pretreated Patients With RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.
Not available
S-EPMC8531995 | biostudies-literature
UnknownThe NHERF1 PDZ2 domain regulates PKA-RhoA-p38-mediated NHE1 activation and invasion in breast tumor cells.
Not available
S-EPMC1855021 | biostudies-literature
UnknownSequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case.
Not available
S-EPMC5786925 | biostudies-literature
UnknownImpact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer.
Not available
S-EPMC6717744 | biostudies-literature
UnknownNHERF1 acts as a molecular switch to program metastatic behavior and organotropism via its PDZ domains.
Not available
S-EPMC3364169 | biostudies-literature
UnknownClinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial.
Not available
S-EPMC5548975 | biostudies-literature
UnknownTocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Not available
S-EPMC7576974 | biostudies-literature
UnknownPanitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial.
Not available
S-EPMC10196928 | biostudies-literature
Sort   by:  
 Page size